EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment

Judit Liaño-Pons iD, Elisa Garde-Lapido iD, Fenja L Fahrig iD, Merle Jäckering iD, Ye Yuan, Stina Andersson iD, Lea Schort, Maria Esteve iD, Sofie Mohlin iD, Oscar C Bedoya-Reina iD, Marie Arsenian-Henriksson iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2427211122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Judit Liaño-Pons und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden. Hauptthemen laut MEDLINE: Neuroblastoma, Peroxiredoxin VI, Glutathione S-Transferase pi, Cell Differentiation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vetenskapsrådet (VR), Cancerfonden (Swedish Cancer Society), Radiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroblastoma (NB) is a heterogeneous childhood cancer, characterized by the amplification of the MYCN oncogene in 40% of the high-risk cases. Our previous work demonstrated that MYCN drives metabolic reprogramming in NB, including upregulation of antioxidant enzymes. Here, we identify peroxiredoxin 6 (PRDX6) as a promising therapeutic target in NB. Pharmacological inhibition of PRDX6 reduces MYCN levels, induces apoptosis, and promotes neuronal differentiation accompanied by lipid droplet accumulation, essential for the phenotypic reprogramming. Moreover, combined inhibition of PRDX6 and glutathione S-transferase Pi 1 (GSTP1), a key antioxidant enzyme needed for PRDX6 activation, demonstrated synergistic effects both in vitro and in vivo. This strategy results in neuronal maturation and initiates downstream pathways distinct from the ones triggered by retinoic acid, the differentiation-inducing agent currently used in clinical practice for NB. Notably, both PRDX6 and GSTP1 are highly expressed in the developing murine adrenal gland, as well as in high-risk, MYCN -amplified NB, correlating with an undifferentiated state and poor prognosis. Together, our results provide insights into the potential of PRDX6 and GSTP1 as therapeutic targets for differentiation induction for children with NB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaPeroxiredoxin VIGlutathione S-Transferase piCell DifferentiationAnimalsHumansMiceN-Myc Proto-Oncogene ProteinCell Line, TumorApoptosis

Stichwörter der Autor:innen

antioxidantschildhood cancerdifferentiation-inducing therapyneuroblastomaoxidative stress

Substanzen

Peroxiredoxin VIGlutathione S-Transferase piN-Myc Proto-Oncogene ProteinGSTP1 protein, humanPRDX6 protein, humanMYCN protein, human

Autor:innen und Institutionen

  • Department of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden.
  • Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund SE-221 45, Sweden.
  • Lund University Cancer Center, Lund University, Lund SE-221 00, Sweden.
  • Lund Stem Cell Center, Lund University, Lund SE-221 84, Sweden.
  • Department of Women's and Children's Health, Karolinska Institutet, Stockholm SE-171 77, Sweden.
  • School of Medical Sciences, Örebro University, Örebro SE-703 62, Sweden.

ORCID-Profile: Judit Liaño-Pons, Elisa Garde-Lapido, Fenja L Fahrig, Merle Jäckering, Stina Andersson, Maria Esteve, Sofie Mohlin, Oscar C Bedoya-Reina, Marie Arsenian-Henriksson

Förderung

  • Vetenskapsrådet (VR)
  • Cancerfonden (Swedish Cancer Society)
  • Radiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet)
  • Barncancerfonden (Swedish Childhood Cancer Foundation)
  • Karolinska Institutet (KI)
  • Sigurd and Elsa Goljes Memorial Fund

Zitieren

APA

Liaño-Pons, J., Garde-Lapido, E., Fahrig, F. L., Jäckering, M., Yuan, Y., Andersson, S., Schort, L., Esteve, M., Mohlin, S., Bedoya-Reina, O. C., & Arsenian-Henriksson, M. (2025). Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2427211122

Vancouver

Liaño-Pons J, Garde-Lapido E, Fahrig FL, Jäckering M, Yuan Y, Andersson S, et al. Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2427211122

BibTeX
@article{LiaoPons2025,
  author = {Liaño-Pons, Judit and Garde-Lapido, Elisa and Fahrig, Fenja L and Jäckering, Merle and Yuan, Ye and Andersson, Stina and Schort, Lea and Esteve, Maria and Mohlin, Sofie and Bedoya-Reina, Oscar C and Arsenian-Henriksson, Marie},
  title = {Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2427211122}
}
Kostenlos starten →